Correspondence 0001493152-25-004214 from Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences, Inc.
Date: Jan. 30, 2025 · CIK: 0000890821 · Accession: 0001493152-25-004214

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-284277

Date

January 30, 2025

Author

Chief

Form

CORRESP

Company

Enveric Biosciences, Inc.

Letter

RE: Enveric Biosciences, Inc.

January 30, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E.

Washington, D.C. 20549

Registration Statement on Form S-1, as amended

(File No. 333-284277)

Acceleration Request

Requested Date: January 30, 2025

Requested Time: 5:15 p.m., Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Enveric Biosciences, Inc. (the “Company”) requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Rasika A. Kulkarni of Dickinson Wright PLLC at (408) 701-6192 to confirm the effectiveness of the Registration Statement or with any questions.

Very truly yours,
Enveric Biosciences, Inc.

Show Raw Text

CORRESP
1
filename1.htm

January
30, 2025

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, N.E.

Washington,
D.C. 20549

RE: Enveric
                                            Biosciences, Inc.

Registration
Statement on Form S-1, as amended

(File
No. 333-284277)

Acceleration
Request

Requested
Date: January 30, 2025

Requested
Time: 5:15 p.m., Eastern Time

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), Enveric Biosciences, Inc. (the “Company”)
requests that the above-referenced Registration Statement (the “Registration Statement”) be declared effective by the Securities
and Exchange Commission (the “Commission”) at the “Requested Date” and “Requested Time” set forth
above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation
Finance of the Commission.

Please
call Rasika A. Kulkarni of Dickinson Wright PLLC at (408) 701-6192 to confirm the effectiveness of the Registration Statement or with
any questions.

    Very truly yours,

    Enveric Biosciences, Inc.

    By:
    /s/
    Joseph Tucker

    Name:
    Joseph
    Tucker, Ph.D.

    Title:
    Chief
    Executive Officer

SecProbe.io